Global Injectable Drug Delivery Equipment Market Size By Type (Conventional Drug Delivery, Novel Drug Delivery), By Application (Hospitals and Clinics, Homecare), By Region, And Segment Forecasts, 202...

The Global Injectable Drug Delivery Equipment Market was valued at USD 42.1 billion in 2023 and is projected to reach USD 78.6 billion by 2031, growing at a CAGR of 8.0% during the forecast period from 2023 to 2031. This market is driven by the rising prevalence of chronic diseases, advancements in biologics and biosimilars, and the increasing adoption of self-injection devices. The demand for injectable drug delivery systems is surging as patients and healthcare providers seek fast, reliable, and less invasive drug administration methods. Growing emphasis on patient compliance, home healthcare, and innovations in device design further bolster market growth.

Drivers:

1. Rise in Chronic Disease Incidence:

The increasing global burden of chronic conditions such as diabetes, cancer, and autoimmune diseases is a significant driver. These conditions often require long-term treatment via injectable drugs, fueling demand for delivery equipment.

2. Technological Advancements in Delivery Devices:

Modern devices such as prefilled syringes, auto-injectors, and wearable injectors have enhanced safety, convenience, and patient adherence. Features like needle-free injections and dose accuracy improve patient outcomes.

3. Shift Toward Self-Administration and Homecare:

There is a rising trend toward home-based treatments, supported by easy-to-use injection systems. This shift reduces healthcare costs and improves patient autonomy, especially for those requiring frequent injections.

Restraints:

1. High Development Costs and Regulatory Barriers:

Designing and manufacturing sophisticated delivery systems require significant investment. Stringent regulations for drug-device combination products also delay time-to-market.

2. Risk of Needlestick Injuries and Infections:

Despite improvements, accidental injuries and infections due to poor handling or reuse of syringes remain concerns, particularly in under-resourced settings.

Opportunity:

1. Growth of Biologics and Biosimilars Market:

The expanding pipeline of biologics and biosimilars provides vast opportunities for injectable devices tailored to these complex therapies.

2. Increasing Healthcare Penetration in Emerging Markets:

Rapid urbanization, rising healthcare expenditure, and improving infrastructure in Asia-Pacific, Latin America, and parts of Africa present untapped potential for market expansion.

Market by System Type Insights:

In 2023, Prefilled Syringes accounted for the largest market share. Their convenience, reduced dosing errors, and lower contamination risk make them the preferred choice across hospitals and home settings. Meanwhile, Auto-injectors are projected to grow fastest due to their increasing use in chronic disease management and emergency care.

Market by End-use Insights:

The Hospitals and Clinics segment led the market in 2023, owing to the high volume of injectable treatments administered in these settings. However, the Homecare Settings segment is rapidly expanding, supported by user-friendly devices, remote patient monitoring, and healthcare decentralization trends.

Market by Regional Insights:

North America dominated the global injectable drug delivery equipment market in 2023, backed by a robust pharmaceutical industry, strong regulatory framework, and widespread adoption of self-injection systems. Asia-Pacific is anticipated to witness the highest CAGR through 2031, driven by population growth, rising disease prevalence, and government initiatives to modernize healthcare delivery.

Competitive Scenario:

Leading players in the market include BD (Becton, Dickinson and Company), Gerresheimer AG, Schott AG, Eli Lilly and Company, Ypsomed AG, West Pharmaceutical Services, Inc., SHL Medical AG, Terumo Corporation, Nipro Corporation, and Owen Mumford Ltd. These companies focus on innovation, strategic partnerships, and geographical expansion.

Key Developments:

In 2023, BD launched a next-generation wearable injector platform designed for high-volume biologic drug delivery.

In 2024, Ypsomed AG entered a strategic agreement with a major pharma firm to supply custom-designed auto-injectors.

In 2025, Gerresheimer AG introduced a smart syringe with integrated sensors to enhance dosing precision and adherence tracking.

Scope of Work – Global Injectable Drug Delivery Equipment Market

Report Metric Details

Market Size (2023) USD 42.1 billion

Projected Market Size (2031) USD 78.6 billion

CAGR (2023–2031) 8.0%

Market Segments System Type (Prefilled Syringes, Auto-injectors, Vials & Ampoules), End-use (Hospitals & Clinics, Homecare, Others)

Growth Drivers Rise in chronic disease prevalence, shift toward homecare, device innovations

Opportunities Growth of biologics and biosimilars, emerging healthcare markets

FAQs:

1) What is the current market size of the Global Injectable Drug Delivery Equipment Market?

The market was valued at USD 42.1 billion in 2023.

2) What is the major growth driver of the Global Injectable Drug Delivery Equipment Market?

The major growth driver is the rising prevalence of chronic diseases coupled with increasing adoption of self-injection systems.

3) Which is the largest region during the forecast period in the Global Injectable Drug Delivery Equipment Market?

North America is the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Injectable Drug Delivery Equipment Market?

The Prefilled Syringes segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Injectable Drug Delivery Equipment Market?

Key players include BD, Gerresheimer AG, Schott AG, Eli Lilly, Ypsomed, West Pharmaceutical Services, SHL Medical, and Terumo Corporation.